On May 28, 2024 Kinomica Ltd., a developer of KScan precision oncology diagnostics, reported the company and collaborators from King’s College London and King’s College Hospital NHS Foundation Trust will be presenting at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, which will be held May 31 – June 4, in Chicago, IL (Press release, King’s College London, MAY 28, 2024, View Source [SID1234643752]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Debashis Sarker MBChB FRCP PhD, Reader in Experimental Oncology, King’s College London and Consultant Medical Oncologist at King’s College Hospital, part of King’s Health Partners, will present the results of the collaboration in a poster titled ‘Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)’.
Details of the poster presentation are as follow:
Poster Session: Developmental Therapeutics—Immunotherapy
Session Date and Time: Saturday June 1, 2024, 9:00 AM – 12:00 PM CDT
Poster Board Number: 110
Abstract Presentation Number: 2631
"We look forward to sharing our important work that for the first time describes a promising biomarker signature with the potential to predict response to the immunotherapy atezolizumab and bevacizumab in patients with aHCC," said Dr Sarker. "An important characteristic of the study is that the biomarkers have been derived from real-world Tru-Cut biopsies taken at diagnosis providing confidence in their potential clinical utility."
"This collaborative effort, drawing on multidisciplinary expertise and rich clinical proteomic data demonstrates the predictive power of the KScan diagnostic platform," said Tim Fell PhD, Executive Chair of Kinomica. "We look forward to extending this collaborative research to determine predictive biomarkers to other approved aHCC therapies and the creation of a multi-drug diagnostic to aid therapy selection."
Kinomica will be attending ASCO (Free ASCO Whitepaper). Please contact us to request a meeting.